Table 2.
Patient # | NKG2D ligands | DNAM-1 ligands | ||
---|---|---|---|---|
MICA | ULBP1 | CD112 | CD155 | |
1 | ++ | + | − | + |
2 | + | − | + | − |
3 | + | + | + | − |
4 | + | − | − | − |
5 | + | − | − | ++ |
6 | ++ | − | + | − |
7 | − | + | − | + |
8 | + | − | + | − |
Expression of ligands for the activating NK cell receptors (NKG2D, DNAM-1) was determined on RMS biopsy sections of 8 ERMS patients by immunohistochemistry (−: no staining or weak membrane staining in <10 % of the tumor cells; +: range of weak staining in at least 10 % of the tumor cells to intense membrane staining in ≤30 % of the tumor cells; ++: intense membrane staining in >30 % of the tumor cells)